Skip to content
Peptide research

Vialox

Also known as Pentapeptide-3V
Category
Skin & Cosmetic
Administration routes
Topical
Regulatory status
Cosmetic ingredient

What it is

A synthetic pentapeptide marketed as a topical alternative to botulinum toxin, blocking acetylcholine at the neuromuscular junction to soften expression lines. The evidence is speculative, resting on in vitro receptor binding rather than independent human trials. Whether it penetrates skin well enough to reach that junction is unresolved. Not an approved drug, sold as a cosmetic ingredient, supply is unregulated research-grade material of uncertain purity.

Read Full record

Studied uses & evidence

Studied uses(5)

  • Reduction of expression wrinkle depth and size

    Speculative

    No published human trial exists, reduction figures come from unpublished supplier marketing data.

  • Decreased skin roughness

    Speculative

    No peer-reviewed instrumental study exists, roughness figures come from unpublished supplier technical literature.

  • Muscle relaxation via nAChR antagonism (in vitro)

    Speculative

    Mechanism is manufacturer-claimed; the 2025 and 2026 studies tested other targets, without directly testing nAChR binding.

Evidence limits

Evidence Level
Preclinical

All clinical evidence for Vialox comes from proprietary data generated by its manufacturer, Pentapharm Ltd. This includes one in vivo study on women aged 30-60 using a half-face design over 28 days, and in vitro muscle contraction assays. These results have not been independently replicated, published in a peer-reviewed dermatology journal, or subjected to rigorous external review. Multiple peer-reviewed cosmeceutical review articles (Errante et al. 2020; Pai et al. 2017; Yotova et al. 2025) acknowledge the mechanism but explicitly note the absence of independent clinical validation. The parent peptide Waglerin-1 has robust peer-reviewed pharmacological data, but whether the truncated Pentapeptide-3 retains meaningful activity after topical application through the stratum corneum remains unproven by independent research.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(6)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Lack of independent clinical validation

    High
  • Uncertain skin penetration and bioavailability

    High
  • Contact dermatitis or skin irritation

    Low
  • Allergic reaction

    Low
  • Quality varies among unregulated products sold online

    Moderate
  • Thermal and pH degradation

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.